PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
NASDAQ:PYPD
Price:
4.94 USD
2.92%
Market Closed
Updated:
May 6, 2024
PolyPid Ltd
Operating Income
|
PolyPid Ltd
Operating Income Peer Comparison
Comparables:
T
TEVA
TARO
I
INCR
MDWD
R
REKA
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Operating Income
-$22.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Income
$3.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Operating Income
$22m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-25%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Operating Income
₪40m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Income
-$15.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-7%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Income
₪5.6m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
See Also
What is PolyPid Ltd's Operating Income?
Operating Income
-22.9m
USD
-22.9m
USD
Based on the financial report for Dec 31, 2023, PolyPid Ltd's Operating Income amounts to -22.9m USD.
What is PolyPid Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-4%
-4%
Over the last year, the Operating Income growth was 41%. The average annual Operating Income growth rates for PolyPid Ltd have been 5% over the past three years , -4% over the past five years .
You don't have any saved screeners yet
